ARCHIVES

Firm Buys Rights To NKT Cells From Beth Israel Deaconess.

This article is from The Cancer Letter archive.

Vol. 26 No. 30 | July 28, 2000

Download PDF Visit The Full Archive

Related Articles

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

June 30, 2006

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

Intramural Program Downsizing Expected; Gallin Named Head of Clinical Center

April 15, 1994

New Grant Program in Physical Activity

March 28, 2003

DCBD Board Okays New Program Projects For Diagnosis Research

June 7, 1985

Socio-Economic Factors, Access To Care, Associated With More Aggressive Cancers

April 27, 2007